Extended Data Fig. 4: Lack of correlation between baseline CD4 T cell subsets and prior daratumumab as last line of therapy in patients on anti-lag-3 arm.
CyTOF was used to assess CD4 T cell subsets (naïve (CCR7 + RO-), central memory (CM; CCR7 + RO + ), effector memory (EM; CCR7-RO + ) and terminal effectors (Term EFF; CCR7-RO-) in pre treatment biospecimens obtained from patients on the Lag-3 arm who did or did not receive prior daratumumab therapy. Data points represent biologically independent samples. a. CD4 T cell subsets in the blood. Data points represent biologically independent samples. Prior Dara: n = 5, no Dara: n = 5. No differences were observed in proportions of circulating CD4 subsets (Naïve, CM, EM, Term EFF) in patients who did or did not receive prior Daratumumab therapy (p=non-significant, 2 tailed Mann Whitney). b. CD4 T cell subsets in the bone marrow. Data points represent biologically independent samples. Prior Dara: n = 3, no Dara: n = 3. No differences were observed in proportions of bone marrow CD4 subsets (Naïve, CM, EM, Term EFF) in patients who did or did not receive prior Daratumumab therapy (p=non-significant, 2 tailed Mann Whitney). Box plots represent median with Q1-Q3 and error bars as min-max.
